<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03822949</url>
  </required_header>
  <id_info>
    <org_study_id>18-0904</org_study_id>
    <secondary_id>R01HL122472</secondary_id>
    <nct_id>NCT03822949</nct_id>
  </id_info>
  <brief_title>Bright Light Therapy in Patients Undergoing Cardiac Surgery</brief_title>
  <official_title>Bright Light Therapy in Patients Undergoing Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elucidate the influence of intense light therapy pretreatment in patients undergoing cardiac&#xD;
      surgery. We hypothesize that intense light exposure is associated with the peripheral&#xD;
      stabilization of Per2 in human buccal swabs and plasma samples before surgery and with a&#xD;
      decrease of Troponin I levels after surgery. In addition, we hypothesize that light therapy&#xD;
      leads to Per2 dependent metabolic optimization in the human cardiac tissue. Therefore, a&#xD;
      small piece of human heart tissue from the right atrium will be collected during cardiac&#xD;
      cannulation, which will be otherwise discarded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PER2 transcript and protein levels in patients undergoing cardiac surgery following intense&#xD;
      light therapy utilizing blood samples, buccal swaps and right atrial myocardium. In addition,&#xD;
      we will examine the correlation of PER2 levels and PER2 related metabolism and perform a&#xD;
      whole genome microarray screen from the collected tissue/blood samples.&#xD;
&#xD;
      Patients will be enrolled 10 to 1 days prior to surgery and will either receive an intense&#xD;
      (bright light) box or a placebo/control device (dim/night light box). The patient will start&#xD;
      using the light box 7 days prior to surgery every morning from 8.30 to 9.00 AM. The patient&#xD;
      will need to keep the box as close as possible to their eyes and not walk away during the&#xD;
      treatment period.&#xD;
&#xD;
      Blood /buccal swabs will be collected on the day of enrollment (10-1 days prior to surgery)&#xD;
      between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM&#xD;
      before anesthesia induction after one week of light/placebo therapy.&#xD;
&#xD;
      A small piece of the right atrial myocardium (which stems from cardiac cannulation and is&#xD;
      otherwise discarded) will be put in liquid nitrogen in the OR and stored for further&#xD;
      analysis.&#xD;
&#xD;
      In addition, we will draw a blood sample 72 hrs. after surgery and determine Troponin I&#xD;
      levels.&#xD;
&#xD;
      Investigating this patient population will give the necessary evidence if light could also be&#xD;
      effective in a perioperative setting to prevent or decrease damage to the myocardium during&#xD;
      high risk cardiac surgery. In addition, it will help us understand if light could be used in&#xD;
      general to prevent or treat heart ischemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Period 2 (Per2) protein levels</measure>
    <time_frame>1-10 days</time_frame>
    <description>Measure of Per2 protein levels related to daylight exposure vs. room light exposure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Experimental: Exposed to Day light</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive an intense (bright light, Square One Wake Up Light NatureBright 10,000 LUX) box. The patient will start using the light box prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of light therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Comparator: Exposed to Room light</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive a placebo/control device (dim/night light box). The patient will start using the light box 7 days prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of placebo therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Day Light</intervention_name>
    <description>Patients are exposed to daylight for up to 10 days prior to surgery</description>
    <arm_group_label>Experimental: Exposed to Day light</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo light</intervention_name>
    <description>Patients are exposed to placebo light for up to 10 days prior to surgery</description>
    <arm_group_label>Sham Comparator: Exposed to Room light</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing primary sternotomy cardiac surgery&#xD;
&#xD;
          -  Subjects in the range of 18 - 90 years old .&#xD;
&#xD;
          -  Patient need to be in sinus rhythm at the time of surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients &lt;18 or &gt;90 years old&#xD;
&#xD;
          -  participation in other clinical trials within the previous 30 days&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  neurological conditions that could impair weaning from ventilator support&#xD;
&#xD;
          -  significant CNS disorders or comorbid irreversible conditions with a six-month&#xD;
             mortality rate more than 50 percent&#xD;
&#xD;
          -  prisoners, or subjects with altered capabilities to make decision will be enrolled&#xD;
&#xD;
          -  medical history of type 2 diabetes&#xD;
&#xD;
          -  patients with atrial fibrillation or use of class III anti-arhythmic drug&#xD;
&#xD;
          -  patients with a left ventricle ejection fraction &lt; 40%&#xD;
&#xD;
          -  patient in emergency condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Eckle, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Eckle, MD, PhD</last_name>
    <phone>7209495646</phone>
    <email>tobias.eckle@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nick Naughton, BS</last_name>
    <phone>303-724-0833</phone>
    <email>NICK.NAUGHTON@CUANSCHUTZ.EDU</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Denver | Anschutz Medical Campus</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220-3706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick M Naughton, BS</last_name>
      <phone>303-724-0833</phone>
      <email>NICK.NAUGHTON@CUANSCHUTZ.EDU</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ucdenver.edu/academics/colleges/medicalschool/departments/Anesthesiology/Research/labs/Dr.%20Eckle%20lab/Pages/default.aspx</url>
    <description>Research homepage</description>
  </link>
  <reference>
    <citation>Bartman CM, Oyama Y, Eckle T. Daytime variations in perioperative myocardial injury. Lancet. 2018 May 26;391(10135):2104. doi: 10.1016/S0140-6736(18)30797-9. Epub 2018 May 24.</citation>
    <PMID>29856340</PMID>
  </reference>
  <reference>
    <citation>Oyama Y, Bartman CM, Gile J, Eckle T. Circadian MicroRNAs in Cardioprotection. Curr Pharm Des. 2017;23(25):3723-3730. doi: 10.2174/1381612823666170707165319. Review.</citation>
    <PMID>28699517</PMID>
  </reference>
  <reference>
    <citation>Bonney S, Hughes K, Harter PN, Mittelbronn M, Walker L, Eckle T. Cardiac period 2 in myocardial ischemia: clinical implications of a light dependent protein. Int J Biochem Cell Biol. 2013 Mar;45(3):667-71. doi: 10.1016/j.biocel.2012.12.022. Epub 2013 Jan 3. Review.</citation>
    <PMID>23291353</PMID>
  </reference>
  <results_reference>
    <citation>Oyama Y, Bartman CM, Gile J, Sehrt D, Eckle T. The Circadian PER2 Enhancer Nobiletin Reverses the Deleterious Effects of Midazolam in Myocardial Ischemia and Reperfusion Injury. Curr Pharm Des. 2018;24(28):3376-3383. doi: 10.2174/1381612824666180924102530.</citation>
    <PMID>30246635</PMID>
  </results_reference>
  <results_reference>
    <citation>Bartman CM, Oyama Y, Brodsky K, Khailova L, Walker L, Koeppen M, Eckle T. Intense light-elicited upregulation of miR-21 facilitates glycolysis and cardioprotection through Per2-dependent mechanisms. PLoS One. 2017 Apr 27;12(4):e0176243. doi: 10.1371/journal.pone.0176243. eCollection 2017.</citation>
    <PMID>28448534</PMID>
  </results_reference>
  <results_reference>
    <citation>Bonney S, Kominsky D, Brodsky K, Eltzschig H, Walker L, Eckle T. Cardiac Per2 functions as novel link between fatty acid metabolism and myocardial inflammation during ischemia and reperfusion injury of the heart. PLoS One. 2013 Aug 20;8(8):e71493. doi: 10.1371/journal.pone.0071493. eCollection 2013.</citation>
    <PMID>23977055</PMID>
  </results_reference>
  <results_reference>
    <citation>Eckle T, Hartmann K, Bonney S, Reithel S, Mittelbronn M, Walker LA, Lowes BD, Han J, Borchers CH, Buttrick PM, Kominsky DJ, Colgan SP, Eltzschig HK. Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. Nat Med. 2012 Apr 15;18(5):774-82. doi: 10.1038/nm.2728.</citation>
    <PMID>22504483</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 27, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

